February 9, 2021 11:31 AM EST

J&J's Erleada/Zytiga combo hits PhIII endpoint — but what about OS?; Targovax loses prostate cancer partner after enrollment struggles

Amber Tong

Max Gelman

Senior Editor

J&J says a combination of Erleada and Zytiga, two of its big prostate cancer drugs, has met the primary endpoint of radiographic progression-free survival in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

J&J's Erleada/Zytiga combo hits PhIII endpoint — but what about OS?; Targovax loses prostate cancer partner after enrollment struggles

Amber Tong

Max Gelman

Senior Editor

Sign up to read this article for free.

Trump taps Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, surgeon general picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

ADC biotech Adcendo nabs $135M Series B as it enters the clinic

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

For CDC, Trump picks Dave Weldon, a former congressman who pushed for vaccine injury claims

From vaccines to psychedelics, five drugmakers on what could change under a Trump administration

J&J's Er­lea­da/Zyti­ga com­bo hits PhI­II end­point — but what about OS?; Tar­go­v­ax los­es prostate can­cer part­ner af­ter en­roll­ment strug­gles

Senior Editor

Sign up to read this article for free.

more like this

J&J's Erleada/Zytiga combo hits PhIII endpoint — but what about OS?; Targovax loses prostate cancer partner after enrollment struggles